Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | ACHE | P22303 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25277811 | 0.91 | EPHX2 (0.46) | EPHX2AAK1CTSKBTKDRD2 | |
| SCHEMBL415355 | 0.83 | MTNR1A (0.41) | EPHX2MTNR1AMTNR1BCTSKBTK | |
| SCHEMBL31730587 | 0.81 | AAK1 (0.39) | EPHX2AAK1DRD2CA1CA2 | |
| SCHEMBL1338041 | 0.80 | CA1 (0.47) | EPHX2MTNR1AMTNR1BAAK1CTSK | |
| SCHEMBL4101120 | 0.80 | CA1 (0.47) | EPHX2MTNR1AMTNR1BAAK1CTSK | |
| SCHEMBL464262 | 0.80 | MTNR1A (0.50) | EPHX2MTNR1AMTNR1BAAK1BTK | |
| SCHEMBL4119861 | 0.80 | CA1 (0.47) | EPHX2MTNR1AMTNR1BAAK1CTSK | |
| SCHEMBL9136687 | 0.76 | CA1 (0.64) | EPHX2MTNR1AMTNR1BBTKDRD2 | |
| SCHEMBL5677299 | 0.76 | CA1 (0.64) | EPHX2MTNR1AMTNR1BBTKDRD2 | |
| SCHEMBL13262741 | 0.76 | CA1 (0.48) | EPHX2MTNR1AMTNR1BCTSKBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716285-B2 | N-hydroxy-benzamids for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-8716285-B2 | N-hydroxy-benzamids for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012031993-A1 | NOVEL N-HYDROXY-BENZAMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065204-A1 | NOVEL N-HYDROXY-BENZAMIDS FOR THE TREATMENT OF CANCER | HNMT, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HRAS | EPHX2 1145/4885MTNR1A 2044/4885MTNR1B 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.